PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 DEC 01 ChemPort single article sales feature unavailable
NEWS 3 APR 03 CAS coverage of exemplified prophetic substances enhanced
NEWS 4 APR 07 STN is raising the limits on saved answers
NEWS 5 APR 24 CA/CAplus now has more comprehensive patent assignee information
NEWS 6 APR 26 USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS 7 APR 28 CAS patent authority coverage expanded
NEWS 8 APR 28 ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS 9 APR 28 Limits doubled for structure searching in CAS REGISTRY
NEWS 10 MAY 08 STN Express, Version 8.4, now available
NEWS 11 MAY 11 STN on the Web enhanced
NEWS 12 MAY 11 BEILSTEIN substance information now available on STN Easy
NEWS 13 MAY 14 DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS 14 MAY 15 INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS 15 MAY 28 CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS 16 JUN 01 CAS REGISTRY Source of Registration (SR) searching enhanced on STN

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 20:45:22 ON 02 JUN 2009

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 20:45:39 ON 02 JUN 2009

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUN 2009 HIGHEST RN 1151607-22-5
DICTIONARY FILE UPDATES: 1 JUN 2009 HIGHEST RN 1151607-22-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10576796.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 20:46:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1636 TO ITERATE

100.0% PROCESSED 1636 ITERATIONS 104 ANSWERS
SEARCH TIME: 00.00.01

L2 104 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 186.36 186.58

FILE 'CAPLUS' ENTERED AT 20:46:38 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Jun 2009 VOL 150 ISS 23
FILE LAST UPDATED: 1 Jun 2009 (20090601/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 2 L2

=> d abs fbib fhitstr 2

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
GI



I



II

AB Novel naphthyridinones [I; R1 = halo, CN, NH2 and derivs., (un)substituted alkyl, hetero/aryl, etc.; R2 = H, NH2 and derivs., (un)substituted alk(en/yn)yl, aryl, etc.; or R1CCR2 = (un)substituted 4-7-membered ring; R3 = H, CF3, OCF3, halo, (un)substituted cyclo/alkyl, alkyloxy; R4 = H, CH2-R5; R5 = H, (un)substituted alk(en/yn)yl, hetero/aryl, etc.; Ar1, Ar2 = independently (un)substituted hetero/aryl] and their pharmaceutically acceptable salts are antagonists and/or inverse agonists of the cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compds. of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. For example, II was prepared in 5 steps: (a) condensation of DMF di-Me acetal with 4-Chlorobenzyl 2,4-dichlorophenyl ketone; (b) cyclocondensation with 2-cyanoacetamide; (c) reaction of pyridinone with POCl3; (d) amination of chloride with MeNH2; and one pot acylation/cyclization of methylated amine with (AcO)2O in Py the presence of DMAP/CH2Cl2. CB1 antagonist/inverse agonist compds. I have IC50s of <1 μM in the CB 1 binding assay; selective CB 1 antagonist/inverse agonist compds. have IC50s 100-fold greater in the CB2 binding assay than in the CB1 assay, and generally have IC50s of ≥1 μM in the CB2 binding assay. Preferred CB1 antagonist/inverse agonist compds. I generally have EC50s of <1 μM in the CB1 functional assay and selective CB1 antagonist/inverse agonists generally have EC50s of >1 μM in the CB2 functional assay.

AN 2005:451381 CAPLUS

DN 143:7697

TI Preparation of substituted naphthyridinones as antagonists and/or inverse agonists of cannabinoid-1 receptor with therapeutic uses
IN Debenham, John S.; Doss, George A.; Madsen-Duggan, Christina B.; Walsh, Thomas F.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2005047285	A1	20050526	WO 2004-US36102		20041029
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2003-517060P	P	20031104
	AU 2004289638	A1	20050526	AU 2004-289638		20041029
				US 2003-517060P	P	20031104
				WO 2004-US36102	W	20041029
	CA 2544191	A1	20050526	CA 2004-2544191		20041029
				US 2003-517060P	P	20031104
				WO 2004-US36102	W	20041029
	EP 1682550	A1	20060726	EP 2004-796813		20041029
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
				US 2003-517060P	P	20031104
				WO 2004-US36102	W	20041029
	CN 1875021	A	20061206	CN 2004-80032652		20041029
				US 2003-517060P	P	20031104
				WO 2004-US36102	W	20041029
	JP 2007510649	T	20070426	JP 2006-538342		20041029
				US 2003-517060P	P	20031104
				WO 2004-US36102	W	20041029
	IN 2006DN01549	A	20070810	IN 2006-DN1549		20060322
				US 2003-517060P	P	20031104
				WO 2004-US36102	W	20041029
	US 20070032517	A1	20070208	US 2006-576796		20060421
				US 2003-517060P	P	20031104
				WO 2004-US36102	W	20041029

OS CASREACT 143:7697; MARPAT 143:7697
IT 852315-35-6P, N-[1-(2,4-Dimethoxybenzyl)-3-acetyl-7-(2,4-dichlorophenyl)-6-(4-chlorophenyl)-1,2-dihydro-2-oxo-1,8-naphthyridin-4-yl]-N-acetylacetamide
RL: BYP (Byproduct); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of naphthyridinones as antagonists and/or

inverse agonists of cannabinoid-1 receptor)
RN 852315-35-6 CAPLUS
CN Acetamide, N-acetyl-N-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-[(2,4-dimethoxyphenyl)methyl]-1,2-dihydro-2-oxo-1,8-naphthyridin-4-yl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d abs fbib fhitstr 1

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
GI



I

AB Synthesis, SAR, and binding affinities are described for a new class of 1,8-naphthyridinones I (R1 = H, Me, Me2CHCH2, MeOCH2CH2, PhCH2, etc.; R2 = H, Me, CN, MeO, Me2N, Me2CH, MeCO; R3 = Me, H2N, Me2N, MeCONH, HOCH2CONH, etc.) as CB1 receptor specific inverse agonists. Food intake, knockout mouse, and pharmacokinetic evaluation of I (R1 = Me; R2 = MeCO; R3 = MeCONH) indicate that this compound is an effective orally active modulator of CB1.

AN 2005:1341986 CAPLUS
DN 144:232941
TI Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists
AU Debenham, John S.; Madsen-Duggan, Christina B.; Walsh, Thomas F.; Wang, Junying; Tong, Xinchun; Doss, George A.; Lao, Julie; Fong, Tung M.; Schaeffer, Marie-Therese; Xiao, Jing Chen; Huang, Cathy R.-R. C.; Shen, Chun-Pyn; Feng, Yue; Marsh, Donald J.; Stribling, D. Sloan; Shearman, Lauren P.; Strack, Alison M.; MacIntyre, D. Euan; Van der Ploeg, Lex H. T.; Goulet, Mark T.
CS Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(3), 681-685
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 144:232941
IT 852315-00-5P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of functionalized 1,8-naphthyridinones and their evaluation as orally active CB1 receptor inverse agonists)
RN 852315-00-5 CAPLUS
CN Acetamide, N-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1,2-dihydro-1-methyl-2-oxo-1,8-naphthyridin-4-yl]- (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT